OPTIMIZATION OF FIXED DURATION TREATMENT OPTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: CURRENT DATA AND FUTURE DIRECTIONS
Introduction of Bruton tyrosine kinase inhibitors (BTKi) and B-cell lymphoma 2 (Bcl-2) antagonists changed the historical approach to chronic lymphocytic leukemia (CLL). Fixed-duration, targeted combination of these novel agents have replaced chemoimmunotherapy and have become preferred treatment op...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924029420 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|